# Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Source: https://onco.cc/trials/nct03393884/  
OnCo record `nct03393884` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Imunon, active and no longer recruiting.

## Summary

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) is a phase 1/2 interventional study registered as NCT03393884 by Imunon, with 130 participants planned, started 2018-09-05 and due to reach its primary completion in 2024-07-25. Interventions recorded: IMNN-001, Carboplatin, Paclitaxel. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03393884
- Phase: 1/2
- Setting: A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Sponsor: Imunon
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT03393884: https://clinicaltrials.gov/study/NCT03393884

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Imunon](https://onco.cc/companies/imunon/)

---
JSON: https://onco.cc/api/v1/entities/nct03393884.json